We talk with Dr. Emanuele Andreano, Head of Serology and Immunology at Fondazione Biotecnopolo di Siena, Italy, who combines immunology, structural biology and artificial intelligence to rapidly develop novel monoclonal antibodies therapies and antiviral vaccine targets.